StackLeaf
Stock · NSE

CIPLA

1,432.20▼ 5.80 (-0.40%)
Last 2 days · 15m candles25/8/2026, 00:34:54
Open: 1,437.10High: 1,438.00Low: 1,411.00Prev: 1,438.00
Positive
2
Neutral
23
Negative
5

News mentioning CIPLA

Sentiment: -10%← All news
VERIFIEDET Finance·5d★ ON YOUR LIST
Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences
AI summary· NEUTRAL
  • ·Cipla has announced its merger with its wholly-owned subsidiary, Inzpera Health Sciences Limited.
  • ·The consolidation is intended to improve resource utilization and achieve greater economies of scale.
  • ·The merger is expected to simplify business processes, reduce administrative expenses, and lower compliance costs.
CIPLA
VERIFIEDET Stocks·12d★ ON YOUR LIST
Cipla Share Price Live Updates: Cipla News
AI summary· NEUTRAL
  • ·Cipla Share Price is currently being updated live.
  • ·There is no additional information available in the body of the article.
  • ·The title indicates that this is a news update regarding Cipla's share price.
CIPLA
VERIFIEDET Stocks·20d★ ON YOUR LIST
Cipla Share Price Live Updates: Cipla Stock Details
AI summary· NEUTRAL
  • ·Cipla's share price is currently being updated live.
  • ·Details regarding Cipla stock are available.
  • ·The provided information pertains to Cipla's stock performance.
CIPLA
VERIFIEDET Markets·21d★ ON YOUR LIST
Nifty Q1 earnings grow 11% to beat estimate, says Motilal Oswal; picks Bharti Airtel, SBI, ICICI Bank among top bets
AI summary· POSITIVE
  • ·Nifty companies' Q1 profits grew 11% year-on-year, exceeding Motilal Oswal's 7% estimate.
  • ·Reliance Industries, JSW Steel, ICICI Bank, Bajaj Finance, and Axis Bank contributed 59% of the incremental earnings growth.
  • ·InterGlobe Aviation, ITC, Dr Reddy’s, Cipla, and Maruti Suzuki were among the companies that negatively impacted earnings growth.
RELIANCEICICIBANKSBINAXISBANKITCMARUTIDRREDDYCIPLAJSWSTEELBHARTIARTLBAJFINANCENIFTYINDIGO
VERIFIEDEconomic Times News·28d★ ON YOUR LIST
US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipeline
AI summary· NEGATIVE
  • ·Dr Reddy's and Cipla reported decreased net profits and operating margins in the June quarter due to a decline in their US business.
  • ·Both companies experienced strong performance in their domestic markets.
  • ·Future growth is anticipated from obesity therapies and specialty product launches, though analysts have lowered earnings forecasts.
CIPLA
VERIFIEDET Markets·28d★ ON YOUR LIST
US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipeline
AI summary· NEGATIVE
  • ·Dr Reddy's and Cipla reported reduced net profits and operating margins in the June quarter due to a decline in their US business.
  • ·The companies' domestic businesses demonstrated strong performance, contributing positively to their overall results.
  • ·Future growth is anticipated from obesity therapies and specialty product launches, though analysts have lowered earnings forecasts.
CIPLA
VERIFIEDET Finance·32d★ ON YOUR LIST
Cipla expects sequential recovery in North America on new product launches despite tariff uncertainty
AI summary· NEUTRAL
  • ·Cipla's net profit dropped 39% to ₹789 crore in the June quarter, impacted by its North America business and margin compression.
  • ·The company achieved record revenue of ₹7,119 crore, driven by strong performance in India, Africa, and emerging markets.
  • ·Cipla anticipates a sequential recovery in its North America business, particularly in the US, due to new product launches and Ventolin supplies.
CIPLA